1707 ET - Drugmaker Eli Lilly suffered its largest one-day loss of market capitalization on record-more than $99 billion-after rival Novo Nordisk struck a deal with CVS that threatens Lilly's growing dominance in the booming anti-obesity drug market. Lilly shares closed down 11.7% at $794.10, their largest one-day percentage decrease since 2008, according to Dow Jones Market Data. CVS's pharmacy-benefits manager will favor coverage of Novo's Wegovy, which means Lilly's competing weight-loss drug Zepbound will be a more costly option for CVS plan members. The Novo-CVS deal is "bad news" for Lilly and will hurt Zepbound's momentum when the new coverage takes effect in July, Leerink Partners analyst David Risinger wrote in a research note. (peter.loftus@wsj.com)
(END) Dow Jones Newswires
May 01, 2025 17:07 ET (21:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。